An observational study in HIV and Hepatitis E, sponsored by Centre Hospitalier de la côte Basque. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-07-17.
Sponsored by Centre Hospitalier de la côte Basque · Observational
Study of seroprevalence of hepatitis E among HIV positive patient in Basque country, France in 2016.
Study of seroprevalence of hepatitis E among patient followed and treated in "centre Hospitalier de la Côte Basque" for HIV infections. Study of acquisition of hepatitis E , and determination of liver status using fibrotest in co-infected patients with hepatis C and / or B.
37 studies on the registry are indexed under Hepatitis E; 9 are open to participants now.
This study's enrollment of 307 is below the median of 436 across 11 observational studies indexed under Hepatitis E.
Browse Hepatitis E studies →Centre Hospitalier de la côte Basque is the lead sponsor of 5 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All patients seropositve for HIV and treated in the" Centre Hospitalier de la côte Basque" are considered for enrollment.
Patient must be > 18 years, and followed or treated in the investigators institution
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Prevalence of immunoglobulin M (IgM) and Immunoglobulin G (IgG) for hepatitis E in blood sample of each patients. Positive sample for both IgM and IgG will be confirmed using polymerase chain reaction (PCR) techniques
Blood samples will be tested for specific immunoglobulins against hepatitis E virus
Time frame: 6 months time period
fibrotest score
patients infected with hepatitis B or hepatitis C viruses will have their liver status determined using fibrotest score.
Time frame: 6 months time period
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier de la côte Basque